File(s) under permanent embargo
The role of depression pharmacogenetic decision support tools in shared decision making
journal contribution
posted on 2019-01-01, 00:00 authored by K Arandjelovic, H A Eyre, E Lenze, Ajeet SinghAjeet Singh, Michael BerkMichael Berk, C BousmanPatients discontinue antidepressant medications due to lack of knowledge, unrealistic expectations, and/or unacceptable side effects. Shared decision making (SDM) invites patients to play an active role in their treatment and may indirectly improve outcomes through enhanced engagement in care, adherence to treatment, and positive expectancy of medication outcomes. We believe decisional aids, such as pharmacogenetic decision support tools (PDSTs), facilitate SDM in the clinical setting. PDSTs may likewise predict drug tolerance and efficacy, and therefore adherence and effectiveness on an individual-patient level. There are several important ethical considerations to be navigated when integrating PDSTs into clinical practice. The field requires greater empirical research to demonstrate clinical utility, and the mechanisms thereof, as well as exploration of the ethical use of these technologies.
History
Journal
Journal of neural transmissionVolume
126Issue
1Pagination
87 - 94Publisher
SpringerLocation
Vienna, AustriaPublisher DOI
eISSN
1435-1463Language
engPublication classification
C Journal article; C1 Refereed article in a scholarly journalCopyright notice
2017, Springer-Verlag GmbH AustriaUsage metrics
Categories
No categories selectedKeywords
AdherenceAntidepressantsDecision support toolPharmacogeneticsPsychoeducationShared decision makingTherapeutic allianceScience & TechnologyLife Sciences & BiomedicineClinical NeurologyNeurosciencesNeurosciences & NeurologySEROTONIN REUPTAKE INHIBITORSPRIMARY-CAREMAJOR DEPRESSIONANTIDEPRESSANT TREATMENTMEDICATION ADHERENCEINFORMATIONOUTCOMESCOMMUNICATIONMETAANALYSISREMISSION
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC